- Pumps and syringes most common delivery method
- U.S. Food and Drug Administration and Health Canada approve new insulin pump
- FDA also OKs glucose monitor app
Last year, the insulin-delivery services market reached $10.4 billion, according to a report from Axis Research Mind.
The market is divided into two segments – invasive devices and non-invasive devices. The most common insulin delivery devices are pumps and syringes, dominating half the market, a position that is expected to continue.
The non-invasive devices segment is forecasted to grow at a compound annual growth rate (CAGR) of 10.5%.
New Insulin Pump Enters U.S. and Canadian Market
Growth in the insulin delivery service market is fueled by new products becoming available to diabetes patients.
In North America, a new insulin pump recently received U.S. Food and Drug Administration and Health Canada approval.
The product, called OneTouch Vibe Plus Insulin Pump and Continuous Glucose Monitoring System, was approved for patients at least two years old. The device allows users to access their glucose numbers through the pump and to transmit them to a mobile app where they can be accessed by up to five caregivers. The numbers also are used to deliver the specific amount of insulin the patient needs.
Transmission is possible through the integration of Dexcom G5 Mobile Continuous Glucose Monitoring System technology.
OneTouch Vibe Plus is manufactured by Animas Corp., part of the Johnson & Johnson Diabetes Care Companies. It is the only device using Dexcom technology that’s approved for children.
“This system will offer kids living with diabetes a sense of freedom and will provide loved ones and caregivers with an insulin delivery and monitoring system that they can trust,” said John Wilson, Worldwide Vice-President of Insulin Delivery of Animas Corp.
OneTouch diabetes products are used by 15 million patients globally and it’s the top brand in the U.S.
Last month, the FDA approved the use of Dexcom G5 MCG Monitoring System as a replacement for finger stick glucose tests. Approval came after two clinical trials.
Previous approvals of Dexcom and other mobile systems required a finger stick test for confirmation of glucose levels.
As recent survey conducted by TD1 Exchanged and published by Diabetes Care, found that 66% of type 1 diabetes patients wear insulin pumps and 9% wear continuous glucose monitors.
Those who don’t use the devices sited cost as the main reason, but patients also said the devices were a hassle to use and cosmetically unappealing.
Of those surveyed, 38% only use insulin pumps, 32% use a pump and monitor, 25% only use daily injections, and 5% use monitors and injections.
- Between 2014 and 2021, Asia-Pacific is forecasted to be the largest region in the invasive devices segment, growing at a (GAGR) of 9.2%. The region is followed by the Middle East and Africa, both growing at a CAGR of 8.6%.
- Other insulin delivery methods include pens, cartridges, inhalers, sprays, patches and jet injectors.
- There are 40 leading companies in the market.